U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H22N2S.C2H4O2
Molecular Weight 370.508
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PECAZINE ACETATE

SMILES

CC(O)=O.CN1CCCC(CN2C3=C(SC4=C2C=CC=C4)C=CC=C3)C1

InChI

InChIKey=COBIOCPXKOZHSU-UHFFFAOYSA-N
InChI=1S/C19H22N2S.C2H4O2/c1-20-12-6-7-15(13-20)14-21-16-8-2-4-10-18(16)22-19-11-5-3-9-17(19)21;1-2(3)4/h2-5,8-11,15H,6-7,12-14H2,1H3;1H3,(H,3,4)

HIDE SMILES / InChI
Molecular Formula C2H4O2
Molecular Weight 60.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C19H22N2S
Molecular Weight 310.456
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

PECAZINE is a phenothiazine derivative that was used as an antipsychotic. It is also an allosteric inhibitor of MALT1 paracaspase activity.

CNS Activity

Approval Year

1957
114
Doses

Doses

DosePopulationAdverse events​
75 mg 3 times / day multiple, oral
Recommended
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Page: p.729
unhealthy, 20-59
n = 33
Health Status: unhealthy
Condition: schizophrenia
Age Group: 20-59
Sex: F
Population Size: 33
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Page: p.729
Disc. AE: Agranulocytosis...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis (3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Page: p.729
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
unhealthy, 35
n = 1
Health Status: unhealthy
Condition: depisssion
Age Group: 35
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
Disc. AE: Agranulocytosis...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
300 mg multiple, oral
Recommended
Dose: 300 mg
Route: oral
Route: multiple
Dose: 300 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Page: p.80
unhealthy, 37.1±1.5
n = 50
Health Status: unhealthy
Condition: schizophrenia
Age Group: 37.1±1.5
Sex: M+F
Population Size: 50
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Page: p.80
Disc. AE: Cycloplegia...
AEs leading to
discontinuation/dose reduction:
Cycloplegia (4%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Page: p.80
900 mg multiple, oral
Highest studied dose
Dose: 900 mg
Route: oral
Route: multiple
Dose: 900 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
unhealthy
n = 2
Health Status: unhealthy
Condition: schizophrenia
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
25 mg 3 times / day multiple, oral
Studied dose
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
unhealthy
n = 2
Health Status: unhealthy
Condition: schizophrenia
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
Disc. AE: Jaundice...
AEs leading to
discontinuation/dose reduction:
Jaundice
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
AEs

AEs

AESignificanceDosePopulation
Agranulocytosis 3%
Disc. AE
75 mg 3 times / day multiple, oral
Recommended
Dose: 75 mg, 3 times / day
Route: oral
Route: multiple
Dose: 75 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Page: p.729
unhealthy, 20-59
n = 33
Health Status: unhealthy
Condition: schizophrenia
Age Group: 20-59
Sex: F
Population Size: 33
Sources:
https://pubmed.ncbi.nlm.nih.gov/14405543
Page: p.729
Agranulocytosis Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
unhealthy, 35
n = 1
Health Status: unhealthy
Condition: depisssion
Age Group: 35
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13377680
Cycloplegia 4%
Disc. AE
300 mg multiple, oral
Recommended
Dose: 300 mg
Route: oral
Route: multiple
Dose: 300 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Page: p.80
unhealthy, 37.1±1.5
n = 50
Health Status: unhealthy
Condition: schizophrenia
Age Group: 37.1±1.5
Sex: M+F
Population Size: 50
Sources:
https://pubmed.ncbi.nlm.nih.gov/13436861
Page: p.80
Jaundice Disc. AE
25 mg 3 times / day multiple, oral
Studied dose
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
unhealthy
n = 2
Health Status: unhealthy
Condition: schizophrenia
Population Size: 2
Sources:
https://pubmed.ncbi.nlm.nih.gov/13444479
Page: p.144
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY562589
https://www.001chemical.com/chem/60-89-9
Alfa Chemistry
60-89-9
https://www.alfa-chemistry.com/cas_60-89-9.htm
Aurora Fine Chemicals LLC
K02.237.593
http://online.aurorafinechemicals.com/info?ID=K02.237.593
Chem Scene
CS-0081367
http://www.chemscene.com/60-89-9.html
Chemspace
CSSS00102561680
https://chem-space.com/CSSS00102561680
Lab Network
LN01302729
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01302729
Matrix Scientific
176622
https://www.matrixscientific.com/176622.html
MedChem Express
HY-121282
https://www.medchemexpress.com/mepazine.html
Molcore
MC562589
https://www.molcore.com/product/60-89-9
Smolecule
S538872
http://www.smolecule.com/products/s538872
THE BioTek
bt-278398
https://www.thebiotek.com/product/inhibitors/bt-278398
VladaChem
VL130984
https://www.vladachem.com/product.php?products=60-89-9
Yuhao Chemical
SY0043
http://www.chemyuhao.com/60-89-9.html
eNovation Chemicals
D931422
https://www.enovationchem.com/ProductDetails.asp?ProductID=D931422
mcule
MCULE-4399173403
https://mcule.com/MCULE-4399173403/
PubMed

PubMed

TitleDatePubMed
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.
2010 Mar 3
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:03:22 GMT 2023
Edited
by admin
on Fri Dec 15 15:03:22 GMT 2023
Record UNII
U42703EIIO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PECAZINE ACETATE
Common Name English
NND 1964
Code English
PHENOTHIAZINE, 10-((1-METHYL-3-PIPERIDYL)METHYL)-, MONOACETATE
Systematic Name English
10-((1-METHYL-3-PIPERIDYL)METHYL)PHENOTHIAZINE ACETATE
Systematic Name English
10H-PHENOTHIAZINE, 10-((1-METHYL-3-PIPERIDINYL)METHYL)-, ACETATE (1:1)
Systematic Name English
MEPAZINE ACETATE
Common Name English
10-((1-METHYL-3-PIPERIDYL)METHYL)-10H-PHENOTHIAZINE MONOACETATE
Systematic Name English
PHENOTHIAZINE, 10-((1-METHYL-3-PIPERIDYL)METHYL)-, ACETATE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C66883
Created by admin on Fri Dec 15 15:03:22 GMT 2023 , Edited by admin on Fri Dec 15 15:03:22 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID80947227
Created by admin on Fri Dec 15 15:03:22 GMT 2023 , Edited by admin on Fri Dec 15 15:03:22 GMT 2023
PRIMARY
PUBCHEM
2834213
Created by admin on Fri Dec 15 15:03:22 GMT 2023 , Edited by admin on Fri Dec 15 15:03:22 GMT 2023
PRIMARY
FDA UNII
U42703EIIO
Created by admin on Fri Dec 15 15:03:22 GMT 2023 , Edited by admin on Fri Dec 15 15:03:22 GMT 2023
PRIMARY
ECHA (EC/EINECS)
246-207-1
Created by admin on Fri Dec 15 15:03:22 GMT 2023 , Edited by admin on Fri Dec 15 15:03:22 GMT 2023
PRIMARY
CAS
24360-97-2
Created by admin on Fri Dec 15 15:03:22 GMT 2023 , Edited by admin on Fri Dec 15 15:03:22 GMT 2023
PRIMARY
NCI_THESAURUS
C75986
Created by admin on Fri Dec 15 15:03:22 GMT 2023 , Edited by admin on Fri Dec 15 15:03:22 GMT 2023
PRIMARY
Related Record Type Details
Structure of PECAZINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of PECAZINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966